Insulin aspart + Insulin aspart protamine


Thông tin thuốc gốc
Chỉ định và Liều dùng
Subcutaneous
Diabetes mellitus
Adult: Available preparation:
Each 100 U/mL susp contains insulin aspart 30% and insulin aspart protamine 70%.

Patient with type 1 diabetes mellitus: 0.5-1 U/kg daily, may be titrated according to patient’s diet, physical activity or concomitant illness. Patient with type 2 diabetes mellitus: As monotherapy or in combination with oral antidiabetic agents or glucagon-like peptide-1 (GLP-1) agonists: Initially, 6 U given in 2 divided doses daily or 12 U once daily. Dosage is individualised and adjusted based on patient’s glycaemic response.
Child: ≥10 years Same as adult dose.
Suy thận
Dosage adjustment may be needed.
Suy gan
Dosage adjustment may be needed.
Cách dùng
Should be taken with food. Administer immediately before or soon after a meal.
Chống chỉ định
Hypersensitivity. Episodes of hypoglycaemia.
Thận trọng
Patients with infections or feverish conditions, adrenal, pituitary or thyroid gland diseases. Not recommended for treatment of diabetic ketoacidosis. Renal and hepatic impairment. Children. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Hypoglycaemia.
Eye disorders: Refraction disorders, diabetic retinopathy.
Gastrointestinal disorders: Diarrhoea, dyspepsia.
General disorders and admin site conditions: Lipodystrophy, oedema, inj site reactions (e.g. pain, erythema, inflammation, pruritus, bruising), influenza-like symptoms.
Immune system disorders: Urticaria.
Investigations: Weight gain.
Metabolism and nutrition disorders: Peripheral oedema.
Musculoskeletal and connective tissue disorders: Back pain.
Nervous system disorders: Headache. Rarely, painful peripheral neuropathy.
Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection, pharyngitis, rhinitis.
Skin and subcutaneous tissue disorders: Rash, eruptions.
Potentially Fatal: Severe hypoglycaemia, hypokalaemia. Rarely, hypersensitivity reactions (e.g. anaphylaxis).
Thông tin tư vấn bệnh nhân
This drug may impair ability to concentrate and react due to hypoglycaemia, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor serum glucose, HbA1c, serum electrolytes, LFTs, renal function and weight at regular intervals during therapy. Assess for signs of hypoglycaemia and hypokalaemia.
Quá liều
Symptoms: Mild to severe hypoglycaemia, hypokalaemia. Management: For mild episodes of hypoglycaemia, may administer oral glucose or sugary products. For unconscious patient with severe hypoglycaemic episodes, may administer IM/SC glucagon (0.5-1 mg) or administer IV glucose if the patient does not respond to glucagon within 10-15 minutes. When the patient becomes conscious, administer oral carbohydrates to prevent relapse.
Tương tác
Increased risk of fluid retention and heart failure with PPAR-γ agonists including thiazolidinediones (e.g. pioglitazone). Increased risk of hypoglycaemia with oral antidiabetic agents, GLP-1 agonists, ACE inhibitors, MAOIs, salicylates, anabolic steroids, sulfonamides, disopyramide, propoxyphene, fibrates, fluoxetine. Hypoglycaemic effect may be decreased by danazol, isoniazid, niacin, oral contraceptives, thiazide diuretics, corticosteroids, atypical antipsychotics (e.g. olanzapine, clozapine), sympathomimetics (e.g. epinephrine, terbutaline, salbutamol), thyroid and growth hormones. ß-blockers, clonidine, guanethidine, reserpine may mask the symptoms of hypoglycaemia. Hypoglycaemia effect may either be potentiated or reduced by lithium salts, octreotide, lanreotide, pentamidine.
Tương tác với thức ăn
Alcohol may either potentiate or reduce the hypoglycaemic effect of insulin aspart + insulin aspart protamine.
Tác dụng
Description: Insulin aspart + Insulin aspart protamine is a biphasic human insulin analogue. It lowers blood glucose by binding to specific membrane-bound receptors on skeletal muscles and fat cells thus stimulating glucose uptake and simultaneously inhibiting glucose production from the liver. It also inhibits lipolysis and proteolysis of fats in adipose tissues and enhances protein synthesis in skeletal muscles.
Onset: 10-20 minutes.
Duration: 18-24 hours.
Pharmacokinetics:
Absorption: Fairly rapidly absorbed from subcutaneous tissue upon inj. Time to peak plasma concentration: 1-1.5 hours.
Distribution: Plasma protein binding: ≤9%.
Metabolism: Rapidly metabolised mainly in the liver but also in kidneys and muscle tissues.
Excretion: Mainly via urine (small amounts as unchanged drug). Elimination half-life: Approx 8-9 hours.
Bảo quản
Unopened vial/cartridge/pen: Store between 2-8°C. Do not freeze. Protect from heat and sunlight. Punctured (in use) vial/cartridge/pen: Store below 30°C. Do not freeze or refrigerate. Protect from sunlight.
Phân loại MIMS
Insulin
Phân loại ATC
A10AD05 - insulin aspart ; Belongs to the class of intermediate-acting combined with fast-acting insulins and analogues. Used in the treatment of diabetes.
Tài liệu tham khảo
Anon. Insulin Aspart Protamine and Insulin Aspart. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/06/2019.

Anon. Insulin Aspart. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 06/06/2019.

Buckingham R (ed). Insulin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/06/2019.

NovoLog Mix 70/30 (Novo Nordisk Inc.). U.S. FDA. https://www.fda.gov/. Accessed 06/06/2019.

Novolog Mix 70/30 Injection, Suspension (A-S Medication Solutions). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/06/2019.

Novolog Mix 70/30 Injection, Suspension (Novo Nordisk). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/09/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Insulin aspart + Insulin aspart protamine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in